Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZL-012 in Overweight and Obese Volunteers
NCT03171415Phase 2Completed
- Sponsor
- Raziel Therapeutics
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Tapencarium in obesity and Overweight (5 arms), sponsored by Raziel Therapeutics. Primary endpoints: Incidence of Treatment-related Adverse Events and Significant Thermogenesis at the Injected Site. Started Jul 2017; status: completed.
02
Drugs
Tapencarium
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03171415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03171415.